• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Galecto Inc.

    8/29/24 5:59:56 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLTO alert in real time by email
    SC 13G/A 1 glto13Agv3.htm 13G / A Template
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549


    SCHEDULE 13G/A


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (AMENDMENT N0. 1)


    Galecto, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    36322Q107

    (CUSIP Number)


    August 29, 2024

    (Date of Event Which Requires Filing of this Statement)



    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

         |_| Rule 13d-1(b)

         |X| Rule 13d-1(c)

         |_|Rule 13d-1(d)








    CUSIP NO. 045354107

        1 Name Of Reporting Persons
      Erik Otto
       

        2 Check The Appropriate Box If A Member Of A
        Group (See Instructions)
    (a)  |_|
        (b)  |_|
         

        3 SEC Use Only
       

        4 Citizenship Or Place Of Organization
      Canada

        5 Sole Voting Power
    Number of   1

    Shares   6 Shared Voting Power
        0
    Beneficially    

    Owned By   7 Sole Dispositive Power
        1
    Each    

    Reporting   8 Shared Dispositive Power
    Person With   0

        9 Aggregate Amount Beneficially Owned By Each Reporting Person
      1

       10 Check If The Aggregate Amount In Row (9) Excludes Certain Shares
        

       11 Percent Of Class Represented By Amount In Row 9
      0%

       12 Type Of Reporting Person (See Instructions)
      IN





    Item 1 (a). Name of Issuer:  Galecto,Inc.
         
    Item 1 (b). Address of Issuer's Principal Executive Offices:
         
                                         75 State Street
                                         Suite 100
                                         Boston, MA  02109
                        
         
    Item 2 (a). Name of Person Filing:  Erik Otto
         
    Item 2 (b). Address of Principal Business Office:   144 West Oakview Place, San Antonio, TX 78209  59401
         
    Item 2 (c). Citizenship:  Canada
         
    Item 2 (d). Title of Class of Securities:  Common
         
    Item 2 (e). CUSIP Number:  36322Q107
         

    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

      (a) |_| Broker or dealer registered under Section 15 of the Act.

      (b) |_| Bank as defined in Section 3(a)(6) of the Act.

      (c) |_| Insurance company as defined in Section 3(a)(19) of the Act.

      (d) |_| Investment company registered under Section 8 of the Investment Company Act.

      (e) |_| An investment adviser in accordance with Rule 13d-1(b)(1) (ii)(E);

      (f) |_| An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

      (g) |_| A parent holding company, in accordance with Rule 13d-1(b)(ii)(G);

      (h) |_| A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

      (i) |_| A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

      (j) |_| Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

    Item 4. Ownership.
         

      (a) Amount beneficially owned:  0
         
      (b) Percent of Class:  0%
         
      (c) Number of shares as to which such person has:

      (i) Sole power to vote or to direct the vote:  1







      (ii) Shared power to vote or to direct the vote:  0
         
      (iii) Sole power to dispose or to direct the disposition of:  1
         
      (iv) Shared power to dispose or to direct the disposition of:  0

     

    Item 5. Ownership of Five Percent or Less of a Class:   Yes
         
    Item 6. Ownership of More than Five Percent on Behalf of Another Person:  Not Applicable
         
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:  Not Applicable
         
    Item 8. Identification and Classification of Members of the Group:  Not Applicable
         
    Item 9. Notice of Dissolution of Group.
         
    Item 10. Certification.

            By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having the purpose or effect.

    SIGNATURE

            After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated:   August 29, 2024

    /s/ Erik Otto                      
    Signature
    Get the next $GLTO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GLTO

    DatePrice TargetRatingAnalyst
    1/7/2026$46.00Outperform
    Leerink Partners
    12/1/2025$32.00Buy
    Guggenheim
    8/6/2021$12.00 → $7.00Outperform
    Credit Suisse
    More analyst ratings

    $GLTO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Galecto with a new price target

    Leerink Partners initiated coverage of Galecto with a rating of Outperform and set a new price target of $46.00

    1/7/26 8:34:02 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Galecto with a new price target

    Guggenheim initiated coverage of Galecto with a rating of Buy and set a new price target of $32.00

    12/1/25 8:28:46 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Credit Suisse reiterated coverage on Galecto with a new price target

    Credit Suisse reiterated coverage of Galecto with a rating of Outperform and set a new price target of $7.00 from $12.00 previously

    8/6/21 10:59:40 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    SEC Filings

    View All

    Galecto Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits

    8-K - Galecto, Inc. (0001800315) (Filer)

    1/6/26 8:15:25 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Galecto Inc.

    S-8 - Galecto, Inc. (0001800315) (Filer)

    1/2/26 5:15:28 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Galecto Inc.

    DEF 14A - Galecto, Inc. (0001800315) (Filer)

    12/31/25 4:17:30 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Hewes L. Becker was granted 264,629 shares (SEC Form 4)

    4 - Galecto, Inc. (0001800315) (Issuer)

    1/7/26 7:34:03 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Hewes L. Becker

    3 - Galecto, Inc. (0001800315) (Issuer)

    1/7/26 7:31:32 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel Winslow Garrett converted options into 680 shares and sold $5,452 worth of shares (255 units at $21.38), increasing direct ownership by 30% to 1,854 units (SEC Form 4)

    4 - Galecto, Inc. (0001800315) (Issuer)

    1/6/26 4:30:13 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Galecto Announces Key Additions to Leadership Team

    Deep hematology/oncology drug development experience added with the appointment of Sherwin Sattarzadeh as Chief Operating Officer and Becker Hewes as Chief Medical Officer DMR-001, a potentially best-in-class mutant calreticulin ("mutCALR") targeting monoclonal antibody, on track for IND submission in mid-2026 with anticipated first-in-human dosing via subcutaneous administration Cash balance, including $285 million raised in November 2025 PIPE, provides financial runway into 2029 to support multiple data milestones, including Ph1 clinical proof-of-concept data for DMR-001 anticipated in 2027 BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. ("Galecto" or the "Company"), a biotech

    1/6/26 8:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (the "Company" or "Galecto") (NASDAQ:GLTO) today announced that the Company's Board of Directors approved the grant of non-qualified stock options to purchase 312,535 shares of the Company's common stock to one new employee (the "Inducement Grant") on December 15, 2025 (the "Grant Date"). The Inducement Grant has been granted pursuant to the Company's 2022 Inducement Plan, as amended from time to time. The Inducement Grant was granted as an inducement material to this individual entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grant has an exercise price per share equal to $3

    12/16/25 5:00:00 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Announces Acquisition of Damora Therapeutics

    Acquisition of Damora and concurrent oversubscribed $285 million private investment positions the company to advance potentially best-in-class portfolio to improve outcomes in patients with Myeloproliferative Neoplasms  Damora Therapeutics, the sixth company launched based on assets developed by Paragon Therapeutics, is advancing a portfolio of anti-mutant calreticulin (mutCALR) targeted therapies, led by DMR-001, a potentially best-in-class monoclonal antibody targeting mutCALR Combined company with complementary assets expected to have financial runway into 2029 to support multiple data milestones, including Phase 1 clinical proof-of-concept data for DMR-001 anticipated in 2027 BOSTON,

    11/10/25 7:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Galecto Inc.

    SC 13G/A - Galecto, Inc. (0001800315) (Subject)

    11/7/24 3:07:49 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Galecto Inc.

    SC 13G - Galecto, Inc. (0001800315) (Subject)

    11/7/24 2:55:56 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Galecto Inc.

    SC 13G/A - Galecto, Inc. (0001800315) (Subject)

    8/29/24 5:59:56 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    Leadership Updates

    Live Leadership Updates

    View All

    Galecto Announces Key Additions to Leadership Team

    Deep hematology/oncology drug development experience added with the appointment of Sherwin Sattarzadeh as Chief Operating Officer and Becker Hewes as Chief Medical Officer DMR-001, a potentially best-in-class mutant calreticulin ("mutCALR") targeting monoclonal antibody, on track for IND submission in mid-2026 with anticipated first-in-human dosing via subcutaneous administration Cash balance, including $285 million raised in November 2025 PIPE, provides financial runway into 2029 to support multiple data milestones, including Ph1 clinical proof-of-concept data for DMR-001 anticipated in 2027 BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. ("Galecto" or the "Company"), a biotech

    1/6/26 8:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

    BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced the appointment of Dr. Amy Wechsler to its Board of Directors. Dr. Wechsler brings a unique combination of expertise and a proven track record of leadership in the healthcare industry. "We are thrilled to welcome Dr. Wechsler to our Board of Directors," said Dr. Carl Goldfischer, Chair of the Board of Galecto. "Amy is a distinguished physician who has board certification in both dermatology and psychiatry. Her experience guiding companies through critical growth stages make her an important add

    10/15/24 8:30:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Adds Experienced Biotech Executive Stephanie Oestreich as Chief Business Officer

    BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the appointment of a highly experienced biotech and pharmaceuticals executive Stephanie Oestreich, PhD, MPA as Chief Business Officer, a newly-created position at Galecto. Dr. Oestreich joins Galecto from Mnemo Therapeutics where she served as Vice President of Operations and Head of Alliance Management. She previously held the role of Executive Vice President at Evotec, a biotech company focusing on developing and delivering new medicines, and has previously served in a number of senior roles

    1/5/22 8:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    Financials

    Live finance-specific insights

    View All

    Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

    Galecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211Bolsters pipeline by obtaining global rights to BRM-1420, a novel dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of acute myeloid leukemia (AML)BRM-1420 has the potential for enhanced clinical effectiveness compared to FLT3 inhibitors alone and has shown synergistic effects with SOC in preclinical models BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that, following an intensive strategic review process, Galecto has determined to f

    10/7/24 8:45:46 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

    Statistically significant reductions observed in ALT, AST and GGT, supporting further development of GB1211 in severe liver diseasesFindings to be discussed in a conference call and virtual webinar today, November 8, 2022, at 8 a.m. ET BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, announced it will discuss topline data and additional analyses from its recently completed Phase 1b/2a GULLIVER-2 trial (NCT05009680), including the observed statistically significant signs of liver protection, in a conference call and virt

    11/8/22 6:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022

    Late-breaking oral and poster presentations include clinical and preclinical data related to GULLIVER-2 clinical trialGalecto to host a webinar at 8:00 a.m. ET on Tuesday, November 8, 2022 to discuss expanded topline data and analysis BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced it will present data from its recently completed Phase 1b/2a GULLIVER-2 trial at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting 2022 being held in Washington, D.C. on November 4-8, 2022. G

    10/31/22 8:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care